Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/ijms24129834
Keywords
mTOR; rapamycin; sapanisertib; glioblastoma; microglia
Ask authors/readers for more resources
Initially used as immunosuppressants in therapy, selective inhibitors of mTORC1 have now been approved for the treatment of solid tumors. Non-selective mTOR inhibitors are being developed in preclinical and clinical studies in oncology to overcome limitations of selective inhibitors, such as tumor resistance. In this study, we compared the effects of a non-selective mTOR inhibitor, sapanisertib, with rapamycin in glioblastoma cell lines and microglia, and found overlapping and diverging effects, especially in the activation of tumor-associated microglia.
Initially introduced in therapy as immunosuppressants, the selective inhibitors of mTORC1 have been approved for the treatment of solid tumors. Novel non-selective inhibitors of mTOR are currently under preclinical and clinical developments in oncology, attempting to overcome some limitations associated with selective inhibitors, such as the development of tumor resistance. Looking at the possible clinical exploitation in the treatment of glioblastoma multiforme, in this study we used the human glioblastoma cell lines U87MG, T98G and microglia (CHME-5) to compare the effects of a non-selective mTOR inhibitor, sapanisertib, with those of rapamycin in a large array of experimental paradigms, including (i) the expression of factors involved in the mTOR signaling cascade, (ii) cell viability and mortality, (iii) cell migration and autophagy, and (iv) the profile of activation in tumor-associated microglia. We could distinguish between effects of the two compounds that were overlapping or similar, although with differences in potency and or/time-course, and effects that were diverging or even opposite. Among the latter, especially relevant is the difference in the profile of microglia activation, with rapamycin being an overall inhibitor of microglia activation, whereas sapanisertib was found to induce an M2-profile, which is usually associated with poor clinical outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available